{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:06:07Z","timestamp":1793127967347,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012729.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000}}],"reference-count":275,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012729.pub3","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T14:36:14Z","timestamp":1701182174000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological treatments in panic disorder in adults: a network meta-analysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Western University; St Thomas Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Meader","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination; University of York; York UK"},{"name":"Cochrane Common Mental Disorders; University of York; York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry; University of Verona; Verona Italy"},{"name":"Cochrane Global Mental Health; University of Verona; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon JC","family":"Davies","sequence":"additional","affiliation":[{"name":"Geriatric Psychiatry Division, CAMH; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion and Human Behavior; Kyoto University Graduate School of Medicine\/School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hissei","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Health Promotion and Human Behavior; Kyoto University Graduate School of Medicine\/School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination; University of York; York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M","family":"Caldwell","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Healthcare; University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden; Chemnitz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran","family":"Tajika","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Kyoto University Hospital; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pompoli","sequence":"additional","affiliation":[{"name":"Private practice, no academic affiliations; Malcesine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; University of Oxford; Oxford UK"},{"name":"Warneford Hospital; Oxford Health NHS Foundation Trust; Oxford UK"},{"name":"Oxford Precision Psychiatry Lab; Oxford Health Biomedical Research Centre; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dawson","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Robertson","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3","article-title":"Panic disorder. A long-term treatment study: fluoxetine vs imipramine","volume":"14","author":"Amore","year":"1999","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0002|cit2","first-page":"435-40","article-title":"Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram","volume":"14","author":"Amore","year":"1999","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Research"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370304800604","article-title":"Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect","volume":"48","author":"Baker","year":"2003","journal-title":"Canadian Journal of Psychiatry\/Revue Canadienne de Psychiatrie"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012729.pub3-BIB0005|cit5","first-page":"S77","article-title":"Reversible monoamine oxidase-A inhibitors in panic disorder","volume":"16","author":"Bakish","year":"1993","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study ofparoxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4088\/JCP.v65n0317","article-title":"Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison","volume":"65","author":"Bandelow","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/jama.283.19.2529","article-title":"Cognitive behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial","volume":"283","author":"Barlow","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004714-199404000-00005","article-title":"Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response","volume":"14","author":"Beauclair","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double-blind clinicaltrial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archpsyc.1993.01820130046008","article-title":"A comparison off luvoxamine, cognitive therapy and placebo in the treatment of panic disorder","volume":"50","author":"Black","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"Bradwejn","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2000-12982","article-title":"The use of the panic and agoraphobia scale (P & A) in a controlled clinical trial","volume":"33","author":"Bandelow","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/ajp.155.5.603","article-title":"Comparison of aerobic exercise, clomipramine and placebo in the treatment of panic disorder","volume":"155","author":"Broocks","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1211\/fact.1999.00054","article-title":"Exercise may help treat panic disorder","volume":"4","author":"Broocks","year":"1999","journal-title":"Focus on Alternative and Complementary Therapies"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/anxi.3070010608","article-title":"Double-blind pilot trial of desipramine versus fluoxetine in panic patients","volume":"1","author":"Bystritsky","year":"1994","journal-title":"Anxiety"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0447.1999.tb05384.x","article-title":"Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study","volume":"99","author":"Caillard","year":"1999","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0018|cit18","first-page":"202","article-title":"Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy","volume":"56","author":"Carter","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","article-title":"Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo","volume":"160","author":"Cross National Collaborative Panic Study Second Phase Investigators","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004714-199408000-00005","article-title":"Adinazolam sustained-release treatment of panic disorder: a double-blind study","volume":"14","author":"Davidson","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","article-title":"Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline","volume":"3","author":"Den Boer","year":"1988","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","article-title":"Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin","volume":"102","author":"Den Boer","year":"1990","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/026988119300700402","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. Effectiveness comparison with imipramine","volume":"7","author":"Gentil","year":"1993","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0024|cit24","unstructured":"A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder. www.gsk-clinicalstudyregister.com\/study\/29060\/223 2008"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0025|cit25","unstructured":"A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/525"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004714-199310000-00004","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"Hoehn-Saric","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1077(199903)14:2<119::AID-HUP77>3.0.CO;2-1","article-title":"Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR","volume":"14","author":"Holland","year":"1999","journal-title":"Human Psychopharmacology Clinical Experimental"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0028|cit28","first-page":"192-9","article-title":"Clomipramine treatment and behaviour therapy with agoraphobic women","volume":"40","author":"Johnston","year":"1995","journal-title":"Canadian Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1037\/0022-006X.58.1.77","article-title":"A comparison of alprazolam and behavior therapy in treatment of panic disorder","volume":"58","author":"Klosko","year":"1990","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S0033291710000930","article-title":"A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder","volume":"41","author":"Koszycki","year":"2011","journal-title":"Psychological Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012729.pub3-BIB0031|cit31","first-page":"S19-S24","article-title":"The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder","volume":"249","author":"Krueger","year":"1999","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4088\/JCP.v60n1205","article-title":"Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder","volume":"60","author":"Bakker","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1600-0447.1997.tb00389.x","article-title":"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"159-63","DOI":"10.1002\/hup.470050209","article-title":"Clinical evaluation of alprazolam in patients with panic disorder; a double-blind comparison with imipramine","volume":"5","author":"Lepola","year":"1990","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"Liebowitz","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"54-60","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00004714-199204000-00004","article-title":"A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder","volume":"12","author":"Lydiard","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0039|cit39","first-page":"183","article-title":"Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder","volume":"29","author":"Lydiard","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"British Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v60n0907","article-title":"Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages","volume":"60","author":"Moroz","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-198904000-00023","article-title":"Actual medication versus therapist guesses: in a blind study, how blind is blind?","volume":"9","author":"Munjack","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"issue":"8","key":"10.1002\/14651858.CD012729.pub3-BIB0044|cit44","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00004714-199410000-00005","article-title":"A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder","volume":"14","author":"Pecknold","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0046|cit46","unstructured":"A randomized, double-blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder http:\/\/clinicaltrials.gov\/show\/NCT00677352"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012729.pub3-BIB0047|cit47","first-page":"60-7","article-title":"Serotoninergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone","volume":"22","author":"Pohl","year":"1989","journal-title":"Psychopathology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1303-7","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro","year":"2001","journal-title":"Brazilian Journal of Medical and Biological Research"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0052|cit52","first-page":"21-6","article-title":"Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone","volume":"25","author":"Robinson","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199710000-00008","article-title":"Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group","volume":"17","author":"Rosenbaum","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/03007999009111500","article-title":"Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study","volume":"12","author":"Savoldi","year":"1990","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0055|cit55","first-page":"19","article-title":"The use of low-dose intranasal midazolam to treat panic disorder: a pilot study.","volume":"53","author":"Schweizer","year":"1992","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","article-title":"Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine","volume":"50","author":"Schweizer","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0887-6185(96)00008-4","article-title":"Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia","volume":"10","author":"Sharp","year":"1996","journal-title":"Journal of Anxiety Disorders"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","article-title":"The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study","volume":"88","author":"Sheehan","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v66n0105","article-title":"Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder","volume":"66","author":"Sheehan","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"107-17","DOI":"10.2190\/KQEJ-MQJR-VK3D-F3HV","article-title":"Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo","volume":"29","author":"Sheikh","year":"1999","journal-title":"International Journal of Psychiatry in Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"112-8","DOI":"10.1097\/00004714-199004000-00006","article-title":"Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial","volume":"10","author":"Taylor","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0063|cit63","first-page":"69-76","article-title":"Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder","volume":"52","author":"Tesar","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012729.pub3-BIB0064|cit64","first-page":"S7-S10","article-title":"Moclobemide and fluoxetine for panic disorder","volume":"249","author":"Tiller","year":"1999","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0065|cit65","first-page":"S271","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: late phase II double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0066|cit66","first-page":"S271","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: late phase II double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0067|cit67","first-page":"S295","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: phase III double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"261-70","DOI":"10.1016\/0165-0327(89)90009-8","article-title":"Response of panic disorder to fixed doses of alprazolam or imipramine","volume":"17","author":"Uhlenhuth","year":"1989","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1590\/S0004-282X2000000600008","article-title":"Double-blind clonazepam vs placebo in panic disorder treatment","volume":"58","author":"Valenca","year":"2000","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF02244898","article-title":"MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine","volume":"112","author":"Van Vliet","year":"1993","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004714-199608000-00005","article-title":"A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder","volume":"16","author":"Vliet","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v63n0107","article-title":"Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder","volume":"63","author":"Versiani","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0074|cit74","first-page":"410","article-title":"Paroxetine versus clomipramine for the treatment of panic disorders: a double-blind randomised study","volume":"14","author":"Zhang","year":"2000","journal-title":"Chinese Mental Health Journal"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0075|cit75","first-page":"119","article-title":"Clobazam in the treatment of anxiety neurosis: a double-blind study","volume":"26","author":"Ananth","year":"1979","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00004714-199402000-00011","article-title":"The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia","volume":"14","author":"Bakish","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012729.pub3-BIB0077|cit77","first-page":"S52","article-title":"Depression comorbid with panic disorder or other anxiety disorders: a 16-week multicentre randomised parallel-group trial of moclobemide versus paroxetine","volume":"10","author":"Baldini Rossi","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment","volume":"45","author":"Ballenger","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0278-5846(91)90049-7","article-title":"The changes of thyroid hormone during pharmacological treatment of panic disorder patients","volume":"15","author":"Balon","year":"1991","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/070674379303800106","article-title":"Changes in appetite and weight during the pharmacological treatment of patients with panic disorder","volume":"38","author":"Balon","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0081|cit81","first-page":"285","article-title":"Treatment of neurotic anxiety with clobazam: double-blind clinical trial against placebo","volume":"9","author":"Barbosa","year":"1980","journal-title":"Clinica Terapeutica"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0082|cit82","first-page":"203","article-title":"Double-blind comparative study of alprazolam (Xanax) and amitriptyline in the treatment of anxiety associated with depression [Studio in doppio cieco di confronto fra alprazolam (Xanax) e amitriptilina nel trattamento dell'ansia associata a depressione]","volume":"29","author":"Bernardi","year":"1988","journal-title":"Minerva Psichiatrica"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0083|cit83","first-page":"97","article-title":"Anti anxiety activity of buspirone: comparative trial with placebo and diazepam [Atividade ansiolitica da buspirona: estudo comparativo com placebo e diazepam]","volume":"37","author":"Bueno","year":"1988","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"11","key":"10.1002\/14651858.CD012729.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1176\/ajp.147.11.1575a","article-title":"Initial reaction and subsequent response to antidepressants in panic patients","volume":"147","author":"Bystritsky","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD012729.pub3-BIB0085|cit85","first-page":"580","article-title":"Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone","volume":"47","author":"Charney","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0086|cit86","first-page":"146","article-title":"Buspirone vs diazepam treatment of anxiety disorders in a double blind study","volume":"3","author":"Chen","year":"1997","journal-title":"Zhongyuan Journal of Psychologic Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0087|cit87","first-page":"99","article-title":"Buspirone vs diazepam in treating anxiety disorders in a double-blind study","volume":"2","author":"Chen","journal-title":"1998"},{"issue":"7","key":"10.1002\/14651858.CD012729.pub3-BIB0088|cit88","first-page":"405","article-title":"Mianserin vs. alprazolam in treating anxiety disorder","volume":"22","author":"Chen","year":"2003","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0089|cit89","first-page":"115","article-title":"Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study","volume":"18","author":"Chouinard","year":"1983","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00464571","article-title":"Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study","volume":"77","author":"Chouinard","year":"1982","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/j.1875-9114.1984.tb03327.x","article-title":"Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder","volume":"4","author":"Cohn","year":"1984","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0924-977X(90)90016-4","article-title":"Beta 2-adrenoceptor antagonism in anxiety","volume":"1","author":"Cooper","year":"1990","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/026988119100500210","article-title":"A comparison of beta-2-adrenoceptor antagonist (ICI 118,551), diazepam and placebo in the treatment of acute anxiety","volume":"5","author":"Cooper","year":"1991","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0094|cit94","first-page":"166","article-title":"Triflubazam (ORF 8063), a new benzodiazepine in anxiety neurosis","volume":"22","author":"Csanalosi","year":"1977","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0095|cit95","first-page":"27","article-title":"Anti-anxiety activity of cannabidiol; double-blind, comparative trial with diazepam and placebo [Efeito ansiol\u00edtico do canabidiol; um estudo comparativo duplo-cego com diazepam e placebo","volume":"4","author":"Cunha","year":"1988","journal-title":"R. Cent. Ci.c Biom\u00e9d. Univ. Fed. Uberl\u00e2ndia"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10401239209150457","article-title":"Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo","volume":"4","author":"Dager","year":"1992","journal-title":"Annals of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000286683","article-title":"The effect of daily oral dosage of diazepam, plasma concentrations and metabolic clearance of diazepam and demethyldiazepam on various constituents of the acute clinical anxiety syndrome","volume":"24","author":"Dasberg","year":"1974","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"11 Pt 2","key":"10.1002\/14651858.CD012729.pub3-BIB0098|cit98","first-page":"4","article-title":"Anxiety: differential diagnosis and treatment from a biologic perspective","volume":"42","author":"Davis","year":"1981","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD012729.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.clinthera.2009.12.010","article-title":"Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder","volume":"31","author":"De Candia","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-2007-1014613","article-title":"A comparative study of suriclone, lorazepam and placebo in anxiety disorder","volume":"22","author":"Jonghe","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0101|cit101","first-page":"397","article-title":"Effectiveness treatment for panic and agoraphobia in comparison between drug and specialized psychological treatment [Il trattamento efficace nella pratica del disturbo di panico e agorafobia in una valutazione comparativa tra psicofarmacologia e trattamento psicologico specifico]","volume":"41","author":"Dell'Erba","year":"2006","journal-title":"Rivista di Psichiatria"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-198701000-00002","article-title":"Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine","volume":"2","author":"den Boer","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0103|cit103","first-page":"127","article-title":"Randomized double-blind study of loxapine as compared with diazepam in therapy of patients with anxiety neuroses [Ricerca in doppio cieco randomizzata sulla loxapina in comparazione al diazepam nell'ambito di pazienti affeti da nevrosi d'ansia]","volume":"95","author":"De Rosa","year":"1980","journal-title":"Clinica Terapeutica"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0028-1094580","article-title":"Prediction of response to chlordiazepoxide and placebo in anxious outpatients: an attempt at replication","volume":"11","author":"Downing","year":"1978","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-0447.1979.tb00554.x","article-title":"Nonspecific factors and side effect complaints. Factors affecting the incidence of drowsiness in drug and placebo treated anxious and depressed outpatients","volume":"60","author":"Downing","year":"1979","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00005053-198303000-00009","article-title":"Physician prognosis in relationship to drug and placebo response in anxious and depressed psychiatric outpatients","volume":"171","author":"Downing","year":"1983","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0107|cit107","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01182877","article-title":"Treatment of negative crises (panic attacks)","volume":"22","author":"Dyukova","year":"1992","journal-title":"Neuroscience and Behavioral Physiology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0109|cit109","first-page":"22","article-title":"Treatment of autonomic attacks (panic attacks)","volume":"26","author":"Dyukova","year":"1993","journal-title":"Journal of Russian and East European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1986.tb02666.x","article-title":"Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo","volume":"73","author":"Evans","year":"1986","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-0327(92)90094-M","article-title":"The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial","volume":"26","author":"Fahy","year":"1992","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0165-1781(89)90215-1","article-title":"Dehydroepiandrosterone-sulfate\/cortisol ratio in panic disorder","volume":"28","author":"Fava","year":"1989","journal-title":"Psychiatry Research"},{"issue":"C","key":"10.1002\/14651858.CD012729.pub3-BIB0113|cit113","first-page":"27","article-title":"A double-blind, placebo-controlled study with tofizopam in anxiety neurosis","volume":"22","author":"Filip","year":"1981","journal-title":"Agressologie"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0114|cit114","first-page":"101","article-title":"Clomipramine and diazepam plasma levels in panic disorder and agoraphobia. Preliminary findings [Concentraciones plasmaticas de clomipramina y diazepam en Desorden de Panico y Agoraphobia. Un estudio preliminar]","volume":"27","author":"Franulic","year":"1989","journal-title":"Revista Chilena de Neuro-Psiquiatria"},{"issue":"10","key":"10.1002\/14651858.CD012729.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","article-title":"Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale","volume":"26","author":"Furukawa","year":"2009","journal-title":"Depression and Anxiety"},{"issue":"11-12","key":"10.1002\/14651858.CD012729.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/j.1552-4604.1980.tb01689.x","article-title":"Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety","volume":"20","author":"Greiss","year":"1980","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0010-440X(98)90043-8","article-title":"Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder","volume":"39","author":"Grilo","year":"1998","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0118|cit118","first-page":"39","article-title":"Treatment of anxiety and depression: a comparative trial of amitriptyline (Laroxyl) and diazepam (Valium)","volume":"11","author":"Hare","year":"1974","journal-title":"Clinical Trials Journal"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0000000000000757","article-title":"No effects of d-cycloserine enhancement in exposure with response prevention therapy in panic disorder with agoraphobia: a double-blind, randomized controlled trial","volume":"37","author":"Hofmeijer-Sevink","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0120|cit120","first-page":"85","article-title":"A comparative study in psychotherapy and drug in treatment of anxiety disorders","volume":"28","author":"Hu","year":"2002","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012729.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","article-title":"Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder","volume":"161","author":"Huppert","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1986.01800010081010","article-title":"Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients","volume":"43","author":"Kahn","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004714-200006000-00008","article-title":"Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam","volume":"20","author":"Kaplan","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-0327(93)90074-T","article-title":"Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo","volume":"28","author":"Keller","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"7","key":"10.1002\/14651858.CD012729.pub3-BIB0125|cit125","first-page":"451","article-title":"Alprazolam in the treatment of neurotic anxiety","volume":"3","author":"Kerry","year":"1983","journal-title":"Pharmatherapeutica"},{"issue":"8618","key":"10.1002\/14651858.CD012729.pub3-BIB0126|cit126","first-page":"1915","article-title":"Nottingham study of neurotic disorder","volume":"2","author":"Klein","year":"1988","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012729.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(90)90033-M","article-title":"Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia","volume":"24","author":"Klerman","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0128|cit128","first-page":"209","article-title":"Comparative study of cloxazolam and placebo in anxiety neurosis [Estudo comparativo sobre o emprego do cloxazolam e placebo em neurose de ansiedade]","volume":"39","author":"Knijnik","year":"1990","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"8","key":"10.1002\/14651858.CD012729.pub3-BIB0129|cit129","first-page":"1233","article-title":"Double blind study with the benzodiazepine derivative Ka-2547 in outpatients with anxiety neurosis [Doppelblindstudie mit dem Benzodiazepin-Derivat Ka-2547 bei ambulanten Patienten mit Angstneurose]","volume":"30","author":"Laakmann","year":"1980","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0130|cit130","first-page":"315","article-title":"Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics","volume":"11","author":"Lapierre","year":"1975","journal-title":"International Journal of Clinical Pharmacology and Biopharmacy"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000118574","article-title":"Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder","volume":"2","author":"Lepola","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0132|cit132","first-page":"199","article-title":"Treatment of panic disorder: pharmacological versus behavioral therapy?","volume":"28","author":"Lorch","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1192\/bjp.162.6.776","article-title":"Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto","volume":"162","author":"Marks","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0134|cit134","first-page":"91","article-title":"Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings","volume":"18","author":"Mavissakalian","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10401230309085686","article-title":"Imipramine vs. sertraline in panic disorder: 24-week treatment completers","volume":"15","author":"Mavissakalian","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"issue":"10 Pt 2","key":"10.1002\/14651858.CD012729.pub3-BIB0136|cit136","first-page":"30","article-title":"Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology","volume":"39","author":"McCurdy","year":"1978","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0137|cit137","first-page":"202","article-title":"Double-blind comparison in parallel groups with nightly single doses of halazepam and placebo[Comparacion dobleciega en grupos paralelos con dosis unicas nocturnas de halazepam y placebo]","volume":"8","author":"McEvilly","year":"1981","journal-title":"Investigacio\u0301n Me\u0301dica Internacional"},{"issue":"7","key":"10.1002\/14651858.CD012729.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4088\/JCP.v68n0710","article-title":"Cost-efficacy of individual and combined treatments for panic disorder","volume":"68","author":"McHugh","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012729.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1176\/ajp.143.11.1464","article-title":"Withdrawal syndrome with gradual tapering of alprazolam","volume":"143","author":"Mellman","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"1 pt B","key":"10.1002\/14651858.CD012729.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00002826-199202001-01046","article-title":"Combination of alprazolam, antidepressive drugs and cognitive behavior therapy in the treatment of panic disorder","volume":"15","author":"Miretzky","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0141|cit141","first-page":"261","volume-title":"Angst und Psychopharmaka: Methoden und Ergebnisse pharmakopsychologischer, pharmakopsychiatrischer und verhaltenspharmakologischer Forschung","author":"Mueller","year":"1986"},{"issue":"12-B Pt 1","key":"10.1002\/14651858.CD012729.pub3-BIB0142|cit142","first-page":"6115","article-title":"Panic: a comparison of four treatment methods","volume":"51","author":"Muncy","year":"1991","journal-title":"Dissertation Abstracts International"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0143|cit143","first-page":"679","article-title":"Ketazolam in the treatment of anxiety: a standard and placebo controlled study","volume":"31","author":"Nair","year":"1982","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"7","key":"10.1002\/14651858.CD012729.pub3-BIB0144|cit144","first-page":"500","article-title":"A multicenter investigation of lorazepam in anxiety neurosis","volume":"15","author":"Nanivadekar","year":"1973","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1590\/S0100-879X2011000400015","article-title":"Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine","volume":"44","author":"Nardi","year":"2011","journal-title":"Brazilian Journal of Medical and Biological Research"},{"issue":"5860","key":"10.1002\/14651858.CD012729.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/bmj.2.5860.202","article-title":"Two anti-anxiety drugs: a psychoneuroendocrine study","volume":"2","author":"Ogunremi","year":"1973","journal-title":"British Medical Journal"},{"issue":"16","key":"10.1002\/14651858.CD012729.pub3-BIB0147|cit147","first-page":"494","article-title":"Comparative clinical evaluation of lorazepam [Essai clinique comparatif lorazepamdiazepam]","volume":"63","author":"Padron","year":"1974","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0148|cit148","unstructured":"Comparative evaluation of efficacy and safety of clonazepam-CR and conventional clonazepam in patients with panic disorder https:\/\/www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=3027&EncHid=&modid=&compid=%27,%273027det%27"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0149|cit149","first-page":"456","article-title":"Double blind study on the use of medazepam in ambulatory therapy] [Etude en doubleaveugle sur l'emploi du medazepam en therapeutique ambulatoire]","volume":"13","author":"Pasini","year":"1972","journal-title":"Cahiers de M\u00e9decine (Europa Medica)"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0150|cit150","unstructured":"A double-blind, placebo-controlled, parallel-group comparison of venlafaxine extended-release capsules and paroxetine in outpatients with panic disorder http:\/\/clinicaltrials.gov\/show\/NCT00044772"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0151|cit151","unstructured":"Pilot study of venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine http:\/\/clinicaltrials.gov\/show\/NCT00195598"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0152|cit152","first-page":"189","article-title":"Efficacy of cloxazolam versus placebo in the therapy of anxious status: double-blind controlled study [Estudo da efic cia do cloxazolam versus placebo na terapia de estados ansiosos: estudo duplocego controlado]","volume":"36","author":"Piedade","year":"1987","journal-title":"Jornal Brasileiro de Psiquiatri"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0153|cit153","first-page":"99","article-title":"Clinical results on the use of lorazepam to treat panic attacks [Risultati clinici sull'uso del lorazepam nel disturbo da attacchi di panico]","volume":"24","author":"Pohl","year":"1989","journal-title":"Rivista di Psichiatri"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-3956(02)00010-9","article-title":"Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder","volume":"36","author":"Pollack","year":"2002","journal-title":"Journal of Psychiatric Research"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/02698811030173009","article-title":"Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder","volume":"17","author":"Pollack","year":"2003","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0006-3223(95)00494-7","article-title":"Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients","volume":"40","author":"Pols","year":"1996","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012729.pub3-BIB0157|cit157","first-page":"655","article-title":"Comparative double-blind clinical trial of SB 5833 and temazapam [Essai clinique compare, en double aveugle, du SB 5833 et du temazepam]","volume":"54","author":"Porta","year":"1974","journal-title":"Bruxelles Medical"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0158|cit158","first-page":"153","article-title":"The \"double-blind\" procedure in study of the anxiolytic effects of the preparation Wy 3498 (Oxazepam). Evaluation of anxiety states with the Hamilton scale (HS) [Procedeul \"dubluorb\" in studiul efectelor anxiolitice ale preparatului Wy 3498 (Oxazepam). Evaluarea starilor de anxietate la scala Hamilton (SH)]","volume":"14","author":"Predescu","year":"1969","journal-title":"Neurologia, Psihiatria, Neurochirurgia"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004714-198902000-00004","article-title":"Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders","volume":"9","author":"Pyke","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0167-4943(02)00111-5","article-title":"Therapy of panic attacks in the elderly","volume":"8","author":"Raffaele","year":"2002","journal-title":"Archives of Gerontology and Geriatrics. Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012729.pub3-BIB0161|cit161","first-page":"272","article-title":"Alprazolam-XR and neuropsychological function in panic disorder","volume":"3","author":"Rapaport","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0010-440X(91)90035-B","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Rifkin","year":"1991","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0163|cit163","first-page":"167","article-title":"A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder","volume":"22","author":"Rizley","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/sj.npp.1300373","article-title":"Independent evaluator knowledge of treatment in a multicenter comparative treatment study of panic disorder","volume":"29","author":"Roll","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archpsyc.58.9.869","article-title":"A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care","volume":"58","author":"Roy-Byrne","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.jcp.0000088907.24613.3f","article-title":"Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy","volume":"23","author":"Rynn","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD012729.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00002826-199202001-01039","article-title":"Personality traits and treatment response in panic disorder","volume":"15","author":"Saiz-Ruiz","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0168|cit168","first-page":"531","article-title":"The intravenous infusion use of chlordemethyldiazepam in neurotic anxiety [Psicopatologia e psicofarmacologia dell'ansia nevrotica A proposito dell'impiego del clordemetildiazepam per infusione venosa]","volume":"3","author":"Scieghi","year":"1986","journal-title":"Rivista Sperimentale Freniatria"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1980.01780140053006","article-title":"Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms","volume":"37","author":"Sheehan","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0170|cit170","first-page":"176","article-title":"A placebo-controlled clinical trial with tofizopam in the treatment of anxiety neurosis","volume":"27","author":"Sladka","year":"1979","journal-title":"Therapia Hungarica"},{"issue":"23","key":"10.1002\/14651858.CD012729.pub3-BIB0171|cit171","first-page":"1392","article-title":"Alprazolam (Tafil) and bromazepam (Lexotan) in the treatment of anxiety: a randomized, double-blind comparison in psychiatric outpatients [Alprazolam (Tafil) og bromazepam (Lexotan) i angstbehandlingen En randomiseret, dobbeltblind sammenligning fra psykiatrisk specialpraksis]","volume":"148","author":"Sonne","year":"1986","journal-title":"Ugeskrift for Laeger"},{"issue":"8-9","key":"10.1002\/14651858.CD012729.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-3223(86)90242-8","article-title":"Immunological response to stress in agoraphobia and panic attacks","volume":"21","author":"Surman","year":"1986","journal-title":"Biological Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012729.pub3-BIB0173|cit173","first-page":"14","article-title":"Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects","volume":"51","author":"Svebak","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD012729.pub3-BIB0174|cit174","first-page":"423","article-title":"A controlled comparison of relaxation and diazepam in panic disorder","volume":"43","author":"Taylor","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0005-7967(85)90011-7","article-title":"Combined pharmacological and behavioral treatment for agoraphobia","volume":"23","author":"Telch","year":"1985","journal-title":"Behaviour Research and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0176|cit176","first-page":"237","article-title":"Evaluation of the anti-anxiety activity of lorazepam in ambulatory patients [Avaliacao da atividade ansiolitica dolorazepam empacientes de ambulatorio]","volume":"20","author":"Terra","year":"1971","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD012729.pub3-BIB0177|cit177","first-page":"4","article-title":"High-potency benzodiazepines for short-term management of panic disorder: the US experience","volume":"51","author":"Tesar","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0022-3956(84)90048-7","article-title":"Anxiety in primary care: is short-term drug treatment appropriate?","volume":"18","author":"Tyrer","year":"1984","journal-title":"Journal of Psychiatric Research"},{"issue":"8605","key":"10.1002\/14651858.CD012729.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(88)92535-4","article-title":"The Nottingham study of neurotic disorder: comparison of drug and psychological treatments","volume":"2","author":"Tyrer","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2008.01157.x","article-title":"Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia","volume":"117","author":"Apeldoorn","year":"2008","journal-title":"Acta Psychiatrica"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00005053-199602000-00015","article-title":"Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia","volume":"184","author":"Van Balkom","year":"1996","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"7","key":"10.1002\/14651858.CD012729.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF03085227","article-title":"First-line treatment of anxiety disorders: a randomized controlled trial [Angststoornissen in de eerste lijn vaak goed te behandelen: Een gerandomiseerd gecontroleerd onderzoek]","volume":"50","author":"Van Boeijen","year":"2007","journal-title":"Huisarts en Wetenschap"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0183|cit183","first-page":"27","article-title":"Evaluation of the use of cloxazolam in patients with moderate anxiety [Avaliacao do emprego do cloxazolam em portadores de ansiedade moderada]","volume":"32","author":"Versiani","year":"1983","journal-title":"Jornal Brasileiro de Psiquiatria"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0184|cit184","first-page":"212","article-title":"Bretazenil: neuroendocrinological profile of a partial benzodiazepine agonist in patients suffering from panic disorder with agoraphobia","volume":"26","author":"Wiesner","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0185|cit185","unstructured":"Woods WS Charney SD Silver MJ Krystal HJ Heninger RG Benzodiazepine receptor antagonist effects in panic disorder 141st Annual Meeting of the American Psychiatric Association, 1988 May 7-12 Montreal, Quebec 1988"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0186|cit186","first-page":"133","article-title":"The control study of mirtazapine in treating patients with panic disorder","volume":"17","author":"Yang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0187|cit187","first-page":"186","article-title":"Effect of citalopram in the treatment of panic disorder","volume":"19","author":"Yang","year":"2006","journal-title":"Shandong Archives of Psychiatr"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000118801","article-title":"Imipramine-induced jitteriness and decreased serum iron levels","volume":"25","author":"Yeragani","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012729.pub3-BIB0189|cit189","first-page":"10","article-title":"The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings","volume":"57","author":"Zajecka","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"27","key":"10.1002\/14651858.CD012729.pub3-BIB0190|cit190","first-page":"728","article-title":"Clinical experiences with the new-generation anxiolytic agent cloxazolam: a double-blind study. [Klinische Erfahrungen mit dem Anxiolytikum der neuen Generation: CloxazolamEine Doppelblindstudie]","volume":"74","author":"Zmorski","year":"1985","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0163-7258(03)00029-9","article-title":"Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence","volume":"98","author":"Allison","year":"2003","journal-title":"Pharmacology & Therapeutics"},{"issue":"7066","key":"10.1002\/14651858.CD012729.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability","volume":"58","author":"Anderson","year":"2000","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/0004867418799453","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder","volume":"52","author":"Andrews","year":"2018","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0196|cit196","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0197|cit197","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423905.154688","volume-title":"American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder","author":"American Psychiatric Association","year":"2009"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0198|cit198","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0199|cit199","unstructured":"American Psychiatric Association Highlights of changes from DSM-IV-TR to DSM-5 www.dsm5.org\/Documents\/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","article-title":"SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis","volume":"106","author":"Bakker","year":"2002","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012729.pub3-BIB0202|cit202","first-page":"47","article-title":"Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012729.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"1-3","key":"10.1002\/14651858.CD012729.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jad.2007.03.013","article-title":"Economic costs of full-blown and subthreshold panic disorder","volume":"104","author":"Batelaan","year":"2007","journal-title":"Journal of Affective Disorders"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011567.pub2","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","author":"Bighelli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012729.pub3-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676.pub2","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"Bighelli","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s001270050098","article-title":"Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS)","volume":"33","author":"Bijl","year":"1998","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0208|cit208","first-page":"405","article-title":"The problem of therapeutic efficacy indices. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677.pub2","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Breilmann","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12962-019-0177-4","article-title":"The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science","volume":"17","author":"Brettschneider","year":"2019","journal-title":"Cost effectiveness and Resource Allocation"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archpsyc.64.7.793","article-title":"Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder","volume":"64","author":"Cameron","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e066084","DOI":"10.1136\/bmj-2021-066084","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials","volume":"376","author":"Chawla","year":"2022","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0217|cit217","unstructured":"CINeMA Confidence in Network Meta-Analysis Institute of Social and Preventive Medicine, University of Bern 2017"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychological Bulletin"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1192\/bjp.bp.115.179275","article-title":"Sponsorship bias in the comparative efficacy of psychotherapy and pharmacotherapy for adult depression: meta-analysis","volume":"210","author":"Cristea","year":"2017","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/02698811211069096","article-title":"Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: a population-based cohort study","volume":"36","author":"Davies","year":"2022","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0223|cit223","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa, 2000 Oct 25-28 2000"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"102664","DOI":"10.1016\/j.ajp.2021.102664","article-title":"Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis","volume":"60","author":"Du","year":"2021","journal-title":"Asian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.151.3.413","article-title":"Panic and panic disorder in the United States","volume":"151","author":"Eaton","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0229|cit229","first-page":"19com12794","article-title":"Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs","volume":"80","author":"Fava","year":"2019","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"204512532097032","DOI":"10.1177\/2045125320970325","article-title":"May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance","volume":"10","author":"Fava","year":"2020","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00228-022-03303-4","article-title":"Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis","volume":"78","author":"Fluyau","year":"2022","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0235|cit235","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004364.pub2","article-title":"Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia","author":"Furukawa","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/wps.20906","article-title":"Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis","volume":"20","author":"Furukawa","year":"2021","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.152.10.1438","article-title":"DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis","volume":"152","author":"Goisman","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0242|cit242","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6. The Cochrane Collaboration, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1001\/jama.2021.4513","article-title":"Risks and benefits of benzodiazepines","volume":"325","author":"Horowitz","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD012729.pub3-BIB0245|cit245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010828.pub2","article-title":"Azapirones versus placebo for panic disorder in adults","author":"Imai","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14 Suppl 1","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","article-title":"The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication","volume":"63","author":"Kessler","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"International Journal of Methods in Psychiatric Research"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02193476","article-title":"Delineation of two drug-responsive anxiety syndromes","volume":"5","author":"Klein","year":"1964","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: evolution, critique and future directions","volume":"28","author":"Lunn D","year":"2009","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","article-title":"Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study","volume":"55","author":"Malizia","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012729.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"1993","author":"Nash","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0256|cit256","volume-title":"Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults [CG113]","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0257|cit257","unstructured":"Nikolakopoulou A Higgins JPT Papakonstantinou T Chaimani A Del Giovane C Egger M Assessing confidence in the results of network meta-analysis (CINeMA) Available at www.biorxiv.org\/content\/10.1101\/597047v1"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","article-title":"An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder","volume":"158","author":"Otto","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1192\/bjp.2021.148","article-title":"Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials","volume":"221","author":"Papola","year":"2022","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0260|cit260","unstructured":"A study of sertraline compared with paroxetine in the treatment of panic disorder https:\/\/clinicaltrials.gov\/study\/NCT00677352"},{"issue":"3","key":"10.1002\/14651858.CD012729.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/rssa.12341","article-title":"Sensitivity of treatment recommendations to bias in network meta-analysis","volume":"181","author":"Phillippo","year":"2018","journal-title":"Journal of the Royal Statistical Society. Series A, (Statistics in Society)"},{"issue":"8","key":"10.1002\/14651858.CD012729.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/M18-3542","article-title":"Threshold analysis as an alternative to GRADE for assessing confidence in guideline recommendations based on network meta-analyses","volume":"170","author":"Phillippo","year":"2019","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/eb-2016-102412","article-title":"Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis","volume":"19","author":"Preti","year":"2016","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0265|cit265","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD012729.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network or multiple-treatments meta-analysis: many names, many benefits","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.2020.164","article-title":"Benzodiazepines: it's time to return to the evidence","volume":"218","author":"Silberman","year":"2021","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0268|cit268","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195369250.001.0001","volume-title":"Anxiety Disorders in Adults: A Clinical Guide","author":"Starcevic","year":"2009"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/7854_2009_35","article-title":"Pharmacologic treatment of panic disorder","volume":"2","author":"Stein","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Valkenhoef","year":"2016","journal-title":"Research Synthesis and Methods"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012729.pub3-BIB0271|cit271","first-page":"13","article-title":"Antidepressants in panic disorder","volume":"14","author":"Wade","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012729.pub3-BIB0272|cit272","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005335.pub2","article-title":"Combined psychotherapy plus benzodiazepines for panic disorder","author":"Watanabe","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1017\/S0033291700029986","article-title":"Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders","volume":"21","author":"Wilkinson","year":"1991","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD012729.pub3-BIB0274|cit274","unstructured":"Winbugs MRC Medical Biostatistics Unit Cambridge 2012"},{"issue":"10","key":"10.1002\/14651858.CD012729.pub3-BIB0275|cit275","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012729.pub2","article-title":"Pharmacological treatments in panic disorder in adults: a network meta-analysis","author":"Guaiana","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:38:14Z","timestamp":1738035494000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012729.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":275,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012729.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}